Fresh hope in advanced breast cancer...

LENTARON (4-hydroxandrostenedione; 4-OHA) is a selective, fortnightly injectable aromatase inhibitor which marks an important development in the hormonal treatment of advanced breast cancer.

Up to now your main option has been between anti-oestrogens and progestogens.

Now LENTARON offers a highly selective way of stopping tumour growth by inhibiting oestrogen synthesis. 1

Quite simply, LENTARON prevents the aromatase enzyme from completing the final step in the conversion of androgen precursors to oestrogen.

With its unique and selective mode of action, LENTARON is not only effective in preventing disease progression, but it also has a prolonged duration of response and a low incidence of side-effects. 1

So for patients who have relapsed on tamoxifen, offer LENTARON and you’ll offer renewed hope.

For a free LENTARON information pack, phone (0403) 272827 and ask for the Medical Information Department.
Review
Is neuroblastoma screening evaluation needed and feasible?
J Estève, I. Parker, P Roy, F Herrmann, S Duffy, D Frappaz, C Lasser, C Hill, H Sancho-Garnier, J Michaelis and T Philip

Guest Editorials
Can we improve the professional and personal fulfilment of doctors in cancer medicine?
I. Fallowfield
The recruitment of patients into clinical trials
HF Tannock

Editorials
Does autocrine growth factor secretion form part of a mechanism which paradoxically protects against tumour development?
T Dawson and D Wyndford-Thomas
Adjuvant therapy for operable breast cancer: more answers, new questions
TJ Perren

Experimental Oncology
The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells
JC Drake, DM Voeller, CJ Allegra and PG Johnston
Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells
BC Pestalozzi, CJ McQueen, TJ Kinsella, JC Drake, MC Glennon, CJ Allegra and PG Johnston

Thermal enhancement of both TNF-α induced systemic toxicity and tumour cure in rats
J van der Zee, GJM van den Aardenweg, GC van Rhoon, AP van den Berg and R de Wit
Variation of growth rate of a rat tumour during a light-dark cycle: correlation with circadian fluctuations in tumour blood flow
KH Hori, G-H Zhang, H-C Li and S Saito

Nitric oxide synthase inhibition irreversibly decreases perfusion in the R3230Ac rat mammary adenocarcinoma
RE Meyer, S Shan, J DeAngelo, RK Dodge, J Bonaventura, ET Ong and MW Dewhirst

Perfusion changes in the RIF-1 tumour and normal tissues after carbenoxolone and nicotinamide, individually and combined
DJ Hynes and NM Bleehen

Fluorozine enhancement of melphalan activity against drug-sensitive/r esistant rhabdomyosarcoma
SM Castellino, HS Friedman, GB Elion, ET Ong, SL Marcelli, R Page, DD Bignier and MW Dewhirst

In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia
E Klumper, R Pieters, ML den Boer, DR Huismans, AH Loonen and AJP Veerman

S-phase specificity of cell killing by Docetaxel (Taxotere®) in synchronised HeLa cells
C Hennequin, N Gioianni and V Favaudon

E09: Relationship between DT-diaphorase levels and response in vitro and in vivo
J Collard, AM Matthew, JA Double and MC Bibby

Preclinical in vitro and in vivo activity of 5,6-dimethyl-xanthene-4-acetic acid
AL Laws, AM Matthew, JA Double and MC Bibby

Temporal heterogeneity in micrometastatic erythrocyte flux in experimental solid tumours
DJ Chaplin and SA Hill

Inhibitory effect of vanadium on rat liver carcinogenesis initiated with diethylnitrosamine and promoted by phenobarbital
A Bishayee and M Chatterjee

Abnormal pattern of post-γ-ray DNA replication in radioresistant fibroblast strains from affected members of a cancer-prone family with Li–Fraumeni syndrome
R Murayama, RA Aubin, W Boonich, WA Blattner and MC Paterson

Co-expression of cdk2/cdk2 and retinoblastoma gene products in colorectal cancer
H Yamamoto, T Monden, K Ikeda, H Iwaza, K Fukuda, M Fukunaga, N Tomita, T Shimano, H Shiozaki and M Monden

Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand binding assay and clinical relevance in breast cancer
JC Newby, RP A Herne, RD Leek, IE Smith, AL Harris and M Dowsett

Expression of fibronectin, fibronectin isoforms and integrin receptors in melanocytic lesions
PG Natali, MR Nicotra, D DiFilippo and A Bigotti

p53 status of head and neck cancer: relation to biological characteristics and outcome of radiotherapy
GD Wilson, PI Richman, S Dische, M1 Saunders, B Robinson, FM Daley and DA Ross

Absence of p53 auto-antibodies in a significant proportion of breast cancer patients
B Vojtesek, J Kovarik, H Dolezalova, R Nemutli, P Havlis, RR Brentani and DP Lane

Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma
J-WR Mulder, JO Baas, MM Polak, SN Goodman and GJA Offerhaus

Clinical Oncology/Epidemiology
Burnout and psychiatric disorder among cancer clinicians
AJ Ramirez, J Graham, MA Richards, A Cull, WM Gregory, MS Leaning, DC Snashall and AR Timothy

Volunteers or victims: patients’ views of randomised cancer clinical trials
M Slevin, J Mossman, A Bowling, R Leonard, W Steward, P Harper, M Mcillmurray and N Thatcher

Does it matter where you live? Treatment variation for breast cancer in Yorkshire
R Sainsbury, L Rider, A Smith and A MacAdam
Phase I study of accelerated FEC with G-CSF (Lenograstim) support
D Bissett, D Jodrell, AN Harnett, T Habeshaw, SB Kaye, D Evans, M Williams and P A Canney

CMF versus alternating CMF/5-FU in the adjuvant treatment of operable breast cancer: A single centre randomised clinical trial (Napels GUN-3 study)
S De Placido, P Ferrone, C Carlonagno, A Morabito, C Pagliarulo, R Lauria, A Marinelli, M De Laurentis, E Varriale, G Petrella, C Guillo and AR Blanco

An evaluation of pre-operative CA15-3 measurement in primary breast cancer
DM O’Hanlon, MJ Kerin, P Kent, D Maher and H Grimes

Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study
Ch Wilschke, M Kraner, AC Budinsky, A Berger, Ch Müller, R Zeillinger, P Speiser, E Kustaba, M Eibl and CC Zielinski

Microvessel quantification in invasive breast cancer by staining for factor VIII-related antigen
Y Ogawa, Y-S Chang, B Nakata, S Takatsuka, K Maeda, T Sawada, Y Kato, K Yoshikawa, M Sakurai and M Sowa

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer
JA Gietema, G-J Veldhuis, H-J Guchelaar, PHB Willemsen, DRA Uges, A Cats, H Boonstra, WTA van der Graaf, DTH Sleijfer, EGE de Vries and NH Mulder

FORTHCOMING PAPERS IN THE BRITISH JOURNAL OF CANCER